Adlai Nortye ANL
NASDAQ ANL
$15.01 +0.26 (+1.76%)
At close: Sep 4, 2026 · 4:00 PM EDT

Adlai Nortye (ANL) Long-Term Investments (2022 - 2026)

Adlai Nortye (ANL) posted quarterly Long-Term Investments of $4.2 million for Q4 2025, up 60600.0% year-over-year from N/an in Q4 2024, and up 1.82% quarter-over-quarter from $4.2 million in Q2 2025.

Analysis

Adlai Nortye (ANL) Long-Term Investments (2022 - 2026) Analysis & Trends

Adlai Nortye (ANL) has reported Long-Term Investments for 4 consecutive years, with $4.2 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Long-Term Investments rose 60600.0% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (up 60600.0% YoY), while the FY2025 annual figure was $4.2 million, up 60600.0% from the prior year.
  • Long-Term Investments climbed to $4.2 million in Q4 2025 per ANL's latest filing, from $4.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $21.3 million in Q4 2022 and bottomed at $7000.0 in Q4 2023.
  • Historically, Long-Term Investments has averaged $5.7 million across 4 years, with a median of $4.2 million in 2024.
  • Annual changes were most pronounced in 2023 — Long-Term Investments plunged 99.97% — and 2025, when it soared 60600.0%.
  • Adlai Nortye's Long-Term Investments stood at $21.3 million in 2022, then slumped by 99.97% to $7000.0 in 2023, then changed by 0.0% to $7000.0 in 2024, then jumped by 60600.0% to $4.2 million in 2025.
  • Business Quant data shows ANL's Long-Term Investments at $4.2 million in Q4 2025, $4.2 million in Q2 2025, and $7000.0 in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.79 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 9.83 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -4.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 1.77 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 22.17 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 372.10 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Adlai Nortye 500.08 Mn 268.19 Mn - 4.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.34 Mn
Dec 31, 2025 4.25 Mn
Jun 30, 2025 4.17 Mn
Dec 31, 2024 4.16 Mn
Jun 30, 2024 4.20 Mn
Dec 31, 2023 129.71 Mn
Dec 31, 2022 94.30 Mn